LY-367,265

From Wikipedia, the free encyclopedia
LY-367,265
Systematic (IUPAC) name
1-(2-(4-(6-fluoro-1H-indol-3-yl)-5,6-dihydropyridin-1(2H)-yl)ethyl)-1,4,5,6-tetrahydro-[1,2,5]thiadiazolo[4,3,2-ij]quinoline 2,2-dioxide
Clinical data
Legal status ?
Identifiers
CAS number 210751-39-6
ATC code ?
PubChem CID 4605800
Chemical data
Formula C24H25FN4O2S 
Mol. mass 452.54 g/mol

LY-367,265 is a drug developed by Eli Lilly, which acts as both a potent and selective antagonist at the serotonin 5-HT2A receptor, and also a selective serotonin reuptake inhibitor (SSRI). It has antidepressant effects in animal studies, reduces glutamate signalling in the brain and increases the analgesic effects of morphine.[1][2][3]


References

  1. Pullar, I. A.; Carney, S. L.; Colvin, E. M.; Lucaites, V. L.; Nelson, D. L.; Wedley, S. (2000). "LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: A comparison with the antidepressant, nefazodone". European journal of pharmacology 407 (1–2): 39–46. doi:10.1016/S0014-2999(00)00728-7. PMID 11050288. 
  2. Wang, S. J. (2005). "Potential antidepressant LY 367265 presynaptically inhibits the release of glutamate in rat cerebral cortex". Synapse 55 (3): 156–163. doi:10.1002/syn.20104. PMID 15602751. 
  3. Durmus, N.; Bagcivan, A.; Gursoy, S.; Altun, I.; Durmus, E. (2011). "Effects of fluoxetine and LY 365265 on tolerance to the analgesic effect of morphine in rats". Acta Physiologica Hungarica 98 (2): 205–213. doi:10.1556/APhysiol.98.2011.2.12. PMID 21616779. 


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.